October 31 2022 - Anaveon, a clinical stage, immuno-oncology company, today announced it will present two posters on its lead program ANV419 at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA.
Poster presentations:
Title: Phase I dose escalation study in patients with advanced solid tumors with ANV419, a novel fusion protein selective for IL-2Rβ/γ
Authors: Christoph Bucher, MD; Guzman Alonso, Dr; Juanita Lopez; Emiliano Calvo; Markus Joerger, MD; Vicky Sanchez Perez, MD; Elena Corral, MD; Daniela Di Blasi, PhD; Kirsten Richter, PhD; Christoph Huber, PhD; Julie Mouton; Silvio Costanzo; Sangeeta Jethwa, MD; Elena Garralda, MD; Heinz Läubli, MD PhD
Presenter: Daniela Di Blasi, PhD
Abstract Number: 631
Date & Time: Thursday, November 10, 2022 from 9 a.m. to 9 p.m. ESTTitle: ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein showing increased efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity
Authors: Christoph Huber, PhD; Kirsten Richter, PhD; Laetitia Petersen; Nicole Egli; Patrizia Murer, PhD
Presenter: Christoph Huber, PhD
Abstract Number: 1099
Date & Time: Thursday, November 10, 2022 from 9 a.m. to 9 p.m. EST
Anaveon is undertaking a Phase I/II study to evaluate the safety, dosing and clinical activity of its lead program, ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors. The Company is pursuing multiple parallel Phase II programs in order to explore the full therapeutic potential of ANV419. In addition, Anaveon continues its work in developing follow-on compounds to expand on the success of ANV419 by delivering the IL-2 agonist to tumor fighting cells and thus expand the therapeutic potential into less immunogenic tumors. Alongside this, the Company is building on its cytokine engineering expertise with preclinical-stage programs harnessing the power of cytokines for therapeutic purposes.
ENDS
Enquiries
JW Communications
Julia Wilson
Email: Julia.wilson@anaveon.com
Tel: +44 (0)7818 430877
About Anaveon:
Anaveon is a clinical stage, biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology. For further information please visit the Company’s website at: www.anaveon.com.